Deal Notes: GlycoMimetics/Pfizer, Pharmacyclics/Servier, TG Therapeutics/Rhizen, Takeda/BioMotiv, Amherst/NovaDel
This article was originally published in Scrip
Pfizer delays Phase III study with GlycoMimetics drug; Pharmacyclics, Servier end agreement; TG Therapeutics licenses drug from Rhizen; Takeda invests $25m in BioMotiv; and Amherst buys NovaDel's ZolpiMist.
You may also be interested in...
Warning letter objects to webpage and meeting exhibit material for excluding any risk information and suggesting mist formulation is superior to oral zolpidem products.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.